Artificial intelligence (AI) has shown great promise for diagnostic imaging assessments. However, the application of AI to support medical diagnostics in clinical routine comes with many challenges. The algorithms should have high prediction accuracy but also be transparent, understandable and reliable. Thus, explainable artificial intelligence (XAI) is highly relevant for this domain. We present a survey on XAI within digital pathology, a medical imaging sub-discipline with particular characteristics and needs. The review includes several contributions. Firstly, we give a thorough overview of current XAI techniques of potential relevance for deep learning methods in pathology imaging, and categorise them from three different aspects. In doing so, we incorporate uncertainty estimation methods as an integral part of the XAI landscape. We also connect the technical methods to the specific prerequisites in digital pathology and present findings to guide future research efforts. The survey is intended for both technical researchers and medical professionals, one of the objectives being to establish a common ground for cross-disciplinary discussions.

Machine learning (ML) algorithms are optimized for the distribution represented by the training data. For outlier data, they often deliver predictions with equal confidence, even though these should not be trusted. In order to deploy ML-based digital pathology solutions in clinical practice, effective methods for detecting anomalous data are crucial to avoid incorrect decisions in the outlier scenario. We propose a new unsupervised learning approach for anomaly detection in histopathology data based on generative adversarial networks (GANs). Compared to the existing GAN-based methods that have been used in medical imaging, the proposed approach improves significantly on performance for pathology data. Our results indicate that histopathology imagery is substantially more complex than the data targeted by the previous methods. This complexity requires not only a more advanced GAN architecture but also an appropriate anomaly metric to capture the quality of the reconstructed images.

Deep learning (DL) has shown great potential in digital pathology applications. The robustness of a diagnostic DL-based solution is essential for safe clinical deployment. In this work we evaluate if adding uncertainty estimates for DL predictions in digital pathology could result in increased value for the clinical applications, by boosting the general predictive performance or by detecting mispredictions. We compare the effectiveness of model-integrated methods (MC dropout and Deep ensembles) with a model-agnostic approach (Test time augmentation, TTA). Moreover, four uncertainty metrics are compared. Our experiments focus on two domain shift scenarios: a shift to a different medical center and to an underrepresented subtype of cancer. Our results show that uncertainty estimates increase reliability by reducing a models sensitivity to classification threshold selection as well as by detecting between 70 and 90% of the mispredictions done by the model. Overall, the deep ensembles method achieved the best performance closely followed by TTA.

Simple Summary Pathology is a cornerstone in cancer diagnostics, and digital pathology and artificial intelligence-driven image analysis could potentially save time and enhance diagnostic accuracy. For clinical implementation of artificial intelligence, a major question is whether the computer models maintain high performance when applied to new settings. We tested the generalizability of a highly accurate deep learning model for breast cancer metastasis detection in sentinel lymph nodes from, firstly, unseen sentinel node data and, secondly, data with a small change in surgical indication, in this case lymph nodes from axillary dissections. Model performance dropped in both settings, particularly on axillary dissection nodes. Retraining of the model was needed to mitigate the performance drop. The study highlights the generalization challenge of clinical implementation of AI models, and the possibility that retraining might be necessary. Poor generalizability is a major barrier to clinical implementation of artificial intelligence in digital pathology. The aim of this study was to test the generalizability of a pretrained deep learning model to a new diagnostic setting and to a small change in surgical indication. A deep learning model for breast cancer metastases detection in sentinel lymph nodes, trained on CAMELYON multicenter data, was used as a base model, and achieved an AUC of 0.969 (95% CI 0.926-0.998) and FROC of 0.838 (95% CI 0.757-0.913) on CAMELYON16 test data. On local sentinel node data, the base model performance dropped to AUC 0.929 (95% CI 0.800-0.998) and FROC 0.744 (95% CI 0.566-0.912). On data with a change in surgical indication (axillary dissections) the base model performance indicated an even larger drop with a FROC of 0.503 (95%CI 0.201-0.911). The model was retrained with addition of local data, resulting in about a 4% increase for both AUC and FROC for sentinel nodes, and an increase of 11% in AUC and 49% in FROC for axillary nodes. Pathologist qualitative evaluation of the retrained model s output showed no missed positive slides. False positives, false negatives and one previously undetected micro-metastasis were observed. The study highlights the generalization challenge even when using a multicenter trained model, and that a small change in indication can considerably impact the model s performance.